These are conditions where the body's immune system makes too many cells or produces too much antibody. It's like the immune system is overactive or making mistakes. This can lead to various health problems.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Immunoproliferative disorders are a group of conditions in which immune cells multiply abnormally or produce too much antibody (immunoglobulin). It is an umbrella label rather than a single disease. The conditions it covers range from common, symptom-free blood test findings that only need monitoring to cancers such as lymphoma and multiple myeloma that need treatment. Most of these conditions involve lymphocytes, the white blood cells that fight infection, or plasma cells, the cells that make antibodies. In lymphoproliferative disorders, which include lymphomas and some leukemias, abnormal B or T lymphocytes keep dividing and can collect in lymph nodes, bone marrow or other organs. In plasma cell disorders, a single family of abnormal cells makes large amounts of one identical antibody, called an M protein (monoclonal protein). This group includes monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, Waldenström macroglobulinemia and light-chain (AL) amyloidosis. Because the label is so broad, the specific diagnosis is what determines symptoms, outlook and treatment.
Most of these conditions have no single identifiable cause. Age is a major factor: MGUS and myeloma become more common as people get older, and MGUS is about twice as common in men as in women. Multiple myeloma and MGUS are also more common in Black Americans, and plasma cell disorders sometimes cluster in families, although most people with an affected relative will not develop one. A weakened immune system raises the risk of lymphoproliferative disorders. People who take long-term medicines that suppress the immune system after an organ transplant can develop post-transplant lymphoproliferative disorder (PTLD), which is often driven by Epstein-Barr virus, the virus that causes mononucleosis. Certain other infections are linked to particular lymphomas. In a rare form called immunoproliferative small intestinal disease, abnormal immune cells grow in the lining of the small intestine. Not every rise in antibody levels is one of these disorders. Infections and inflammatory conditions commonly raise many different antibodies at once, which is a normal immune response rather than a clonal disorder.
Many plasma cell disorders are first found by chance on blood tests done for another reason. When one is suspected, three blood tests are used together. Serum protein electrophoresis separates the proteins in blood and shows whether there is an M protein and how much. Immunofixation confirms that the protein comes from a single cell family and identifies its type (for example IgG or IgM). A free light chain test measures the small antibody pieces called kappa and lambda light chains; an unbalanced ratio between them can point to a plasma cell disorder. Urine tests may also look for these proteins. A complete blood count, calcium and kidney function tests check whether the condition is affecting the body, since anemia, high calcium, kidney damage and bone lesions are signs that a plasma cell disorder has become active myeloma rather than MGUS. Depending on the results, a doctor may recommend a bone marrow biopsy or bone imaging. For suspected lymphoma or another lymphoproliferative disorder, a biopsy of an enlarged lymph node or affected tissue is usually needed to confirm the diagnosis and identify the exact type. Imaging scans then show where in the body the disease is. Rare forms affecting a single organ, such as the small intestine, are diagnosed by biopsy of that organ.
Treatment depends entirely on which disorder is present and whether it is causing symptoms or organ damage. MGUS is not treated. People with low-risk MGUS usually do not need a bone marrow biopsy and instead have blood tests repeated over time to watch for change. Smoldering myeloma and some slow-growing lymphomas are also often watched closely without treatment until symptoms or signs of organ damage appear, an approach called watchful waiting or active monitoring. When treatment is needed, it is designed for the specific diagnosis. Lymphomas and myeloma may be treated with chemotherapy, targeted drugs that act on specific features of the abnormal cells, immunotherapy that helps the immune system attack them, radiation, or a stem cell transplant. Side effects depend on the specific treatment, and weighing them against the expected benefit is a central part of planning with a hematologist or oncologist (a blood or cancer specialist). Some forms have their own first steps. For PTLD after an organ transplant, the transplant team usually begins by reducing immunosuppressive medicines, which lets the immune system fight the abnormal cells, and adds rituximab, an antibody medicine that targets B cells, or chemotherapy if needed. Reducing immunosuppression has to be balanced against the risk of organ rejection. Early immunoproliferative small intestinal disease has been treated with antibiotics and nutritional support, while advanced disease needs chemotherapy.
The outlook ranges widely. MGUS is present in about 4% of adults and most people with it never develop a related cancer. The non-IgM type progresses to myeloma or AL amyloidosis at a rate of about 1% per year, and the IgM type progresses to Waldenström macroglobulinemia at about 1.5% per year. In practice, MGUS usually means periodic blood tests rather than changes to daily life. Smoldering myeloma carries a higher risk, about 10% per year for the first five years, so follow-up is more frequent. For lymphoma, myeloma and related cancers, the course depends on the type and stage. Some are slow-growing and managed over many years with periods of monitoring and treatment; others are fast-growing and treated intensively from the start. Fatigue, more frequent infections and the effects of treatment can affect work and daily routines. Ongoing care usually involves regular blood tests, scans and visits with a specialist team, even during remission.
Arrange an evaluation if you notice swollen lymph nodes in the neck, armpits or groin that do not go away, unexplained weight loss, fevers, soaking night sweats, persistent bone pain (often in the back or ribs), ongoing fatigue or infections that keep coming back. Chronic diarrhea with weight loss also deserves assessment. If you have MGUS or another monitored condition, contact your care team before your next scheduled check if you develop new bone pain, numbness or tingling in the hands or feet, swelling in the legs, foamy urine or unusual shortness of breath, since these can signal progression or organ involvement. Transplant recipients should tell their transplant team promptly about new swollen glands, fevers or unexplained weight loss.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Immunoproliferative Disorders is like, what's helped you, or ask the community a question.